. Author manuscript; available in PMC: 2021 Mar 29.

Published in final edited form as: Ann Neurol. 2010 Dec 28;69(2):375–388. doi: 10.1002/ana.22237

TABLE 2:

Motor Performance of the Right/Affected Hand

Tasks	Unit (mean ± SD)	Controls	Patients_PBO		Patients_RBX		Agent		Session		Agent × Session
Tasks	Unit (mean ± SD)	Controls	BASE	DRUG	BASE	DRUG	F(1,10)	p	F(1,10)	p	F(1,10)	p
ARAT		57	43	44	42	44	0.007	0.937	6.852	0.026^*	2.664	0.134
		0	11	11	12	12
Hand grip strength	kPa	89.27	56.00	57.36	54.82	62.64	0.459	0.513	10.195	0.010^*	6.792	0.026^*
Hand grip strength	kPa	19.79	23.50	20.88	24.50	28.43
Index finger-tapping	Frequency (Hz)	4.65	2.75	2.96	2.73	3.20	1.340	0.274	20.848	0.001^**	8.382	0.016^*
	Frequency (Hz)	0.82	1.33	1.23	1.35	1.27
	Amplitude (mm)	33.23	26.31	23.09	23.59	24.72	0.164	0.694	0.425	0.529	1.925	0.195
	Amplitude (mm)	6.17	15.47	13.89	14.60	12.48
Rapid pointing movements	Frequency (Hz)	1.81	0.95	0.99	1.00	1.09	3.354	0.097	4.227	0.067	1.595	0.235
	Frequency (Hz)	0.52	0.67	0.60	0.64	0.66
	Amplitude (mm)	306.73	303.95	295.67	304.60	300.36	0.135	0.721	1.425	0.260	0.245	0.631
	Amplitude (mm)	19.44	24.57	29.79		10.00	22.39

Means and SDs are shown. Post hoc paired t tests showed that compared with the respective BASE session, grip power and index finger-tapping frequency were significantly higher after treatment with RBX (FDR corrected, p < 0.05) but not after PBO administration.

p < 0.05.

^**

p < 0.01.

ARAT = action research arm test; BASE = baseline; DRUG = postadministration session; FDR = false discovery rate; PBO = placebo; RBX = reboxetine; SD = standard deviation.